Home > Insider Trading > Filing (0001062993-21-000354)

Filing Details

Accession Number:: 0001062993-21-000354
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-13 20:39:00
Reporting Period:: 2021-01-11

Accepted Time:: 2021-01-13 20:39:00
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1649094	Vaxcyte Inc.	PCVX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1551966	Lorne Robert Hopfner	C/O Vaxcyte, Inc. 353 Hatch Drive Foster City CA 94404		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-01-11	12,480	$25.42	2,064,875	No	4	S	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
Common Stock	Disposition	2021-01-11	24,980	$26.69	2,039,895	No	4	S	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
Common Stock	Disposition	2021-01-11	12,206	$27.02	2,027,689	No	4	S	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
Common Stock	Disposition	2021-01-12	17,666	$26.35	2,010,023	No	4	S	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
Common Stock	Disposition	2021-01-12	901	$27.05	2,009,122	No	4	S	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
Common Stock	Disposition	2021-01-13	26,010	$25.90	1,983,112	No	4	S	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
Common Stock	Disposition	2021-01-13	3,100	$26.34	1,980,012	No	4	S	Indirect	By Pivotal bioVenture Partners Fund I, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
No	4	S	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
No	4	S	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
No	4	S	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
No	4	S	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
No	4	S	Indirect	By Pivotal bioVenture Partners Fund I, L.P.
No	4	S	Indirect	By Pivotal bioVenture Partners Fund I, L.P.

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.99, inclusive. The reporting person undertakes to provide to Vaxcyte, Inc., any security holder of Vaxcyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6), (7), (8) and (9) to this Form 4.
The shares are held of record by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd, (the "Ultimate General Partner"). The board of directors of the Ultimate General Partner may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal. Rob Hopfner is the managing partner of Pivotal bioVenture Partners Investment Advisor LLC and may be deemed to share voting and investment power over the shares held directly by Pivotal bioVenture Partners. Mr. Hopfner disclaims beneficial ownership over such shares except to the extent of any pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.99, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.08, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.90 to $26.89, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.90 to $27.36, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.26 to $26.25, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.26 to $26.42, inclusive.